| Sep 26 |
Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results
|
| Sep 9 |
Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
|
| Aug 28 |
Palatin stock climbs 8% on Phase 3 testing update for PL9643
|
| Aug 28 |
FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)
|
| Aug 23 |
Palatin Technologies doses first subject in Phase II obesity treatment trial
|
| Aug 22 |
First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity
|
| Jun 21 |
Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds
|
| Jun 21 |
Palatin initiates Bremelanotide-PDE5i Phase II trial for ED
|
| Jun 20 |
Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)
|
| Jun 13 |
Palatin Technologies commences Phase II study of obesity treatment
|
